<DOC>
	<DOCNO>NCT01827371</DOCNO>
	<brief_summary>Imvamune ( license name MVA develop smallpox vaccine ) test 2,000 individual path licensure . This study Phase II evaluate three different immunization schedule two different mode delivery . The study look condense schedule . Study randomize subject one four arm .</brief_summary>
	<brief_title>Phase II Trial Assess Safety Immunogenicity IMVAMUNE®</brief_title>
	<detailed_description>This Phase II , randomize , open-label immunogenicity safety study different immunization schedule delivery system ( syringe needle vs. Stratis™ ) healthy , vaccinia-naïve adult 18 year 40 year age , inclusive . Approximately 352 subject enrol randomized one four study arm . Study Arm A ( N=88 ) receive two dose regimen IMVAMUNE® ( 1x10^8 TCID50/0.5 mL per dose ) via SC route use syringe needle Day 1 29 . Study Arm B ( N=88 ) receive two dose regimen IMVAMUNE® ( 1x10^8 TCID50/0.5 mL per dose ) via SC route use syringe needle Day 1 15 . Study Arm C ( N=88 ) receive two dose regimen IMVAMUNE® ( 1x10^8 TCID50/0.5 mL ) via SC route use syringe needle Day 1 22 . Study Arm D ( N=88 ) receive two dose regimen IMVAMUNE® ( 1x10^8 TCID50/0.5 mL ) via SC route use Stratis™ Day 1 29 . Immunogenicity assessment perform use ELISA PRNT . Safety assessment do via solicit injection site systemic reaction . Unsolicited AEs collect 28 day post last injection SAEs duration subject ' study participation . Safety laboratory assessment perform baseline 14 day vaccination . Primary outcome measure : For subject , peak PRNT define high titer among available measurement post second vaccination ; Occurrence solicit local injection site reaction subject receive vaccine via Stratis™ compare syringe needle administration collect memory aid clinic assessment . Parent protocol sub-study 13-0027 .</detailed_description>
	<mesh_term>Smallpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . 18 40 year age , inclusive . 2 . Read , sign , date informed consent document . 3 . Available followup plan duration study ( six month last immunization ) . 4 . Acceptable medical history screen evaluation limit physical assessment . 5 . If subject female childbearing potential , negative serum urine pregnancy test screening within 24 hour prior vaccination . 6 . If subject female childbearing potential* , agree practice abstinence** use acceptable contraception*** 56 day last vaccination order avoid pregnancy : * woman consider childbearing potential unless postmenopausal ( &gt; /= 1 year without menses ) surgically sterilize ( tubal ligation , bilateral oophorectomy , hysterectomy ) **No sexual intercourse men ( vaginal penetration penis , coitus ) ***Acceptable contraception method restrict effective device ( IUDs , NuvaRing® ) license hormonal product use method minimum 30 day prior vaccination , condom spermicidal agent , monogamous relationship vasectomize partner vasectomize 6 month prior study entry , successful Essure placement document confirmation test least 3 month procedure , FDAapproved contraceptive method 7 . Negative test HIV . 8 . Alanine Aminotransferase ( ALT ) &lt; 1.25 time central lab upper limit normal . 9 . Negative hepatitis B surface antigen negative antibody hepatitis C virus . 10 . Negative urine glucose negative trace urine protein dipstick urinalysis . 11 . Adequate renal function ( define serum creatinine exceed central lab 's upper limit normal ) . 12 . Electrocardiogram ( ECG ) clinically significant abnormalities* * e.g. , complete leave right bundle branch block , incomplete leave bundle branch block sustain ventricular arrhythmia , two PVC 's row , ST elevation consistent ischemia ) 13 . Acceptable hematology parameter : Hemoglobin ( Hgb ) equal low limit central lab normal ( sexspecific ) ; White Blood Cell ( WBC ) &gt; 3,800 &lt; 10,900/mm^3 ; Platelets &gt; /=120,000/mm^3 14 . Body mass index &gt; /=18.5 &lt; 35 . 15 . Be able understand comply plan study procedure . 1 . History immunodeficiency . 2 . Typical vaccinia scar . 3 . Known suspected history smallpox vaccination include MVA alone vector , well investigational smallpox vaccine . 4 . Military service prior 1991 January 2003 . 5 . Known suspected significant underlying illness include , limited , clinically significant liver disease , diabetes mellitus , moderate severe kidney impairment . 6 . Malignancy ( include squamous cell skin cancer basal cell skin cancer unless vaccination site ) history skin cancer vaccination site . 7 . Active autoimmune disease . Persons vitiligo thyroid disease ( e.g. , take thyroid hormone replacement ) exclude . 8 . History myocardial infarction , angina , congestive heart failure , cardiomyopathy , stroke transient ischemic attack , heart condition care doctor* *Subjects clinically relevant heart murmur , i.e. , without pathological ECG/arrhythmias treatment exclude . 9 . Systolic blood pressure &gt; /= 150mmHg diastolic blood pressure &gt; /= 100mmHg . 10 . Ten percent great risk develop myocardial infarction coronary death within next 10 year use National Cholesterol Education Program 's ( NCEP ) risk assessment tool* *NOTE criterion applies subject 20 year age old AND least one follow apply : smoke cigarette past month , and/or hypertension ( define systolic blood pressure &gt; 140 mm Hg ) antihypertensive medication , and/or family history coronary heart disease male firstdegree relative ( father brother ) &lt; 55 year age female firstdegree relative ( mother sister ) &lt; 65 year age URL NCEP risk assessment tool : http : //cvdrisk.nhlbi.nih.gov/calculator.asp ( subject HDL great 100mg/dl please enter 100 tool ) 11 . Highdose corticosteroid use great 2 week duration within three month prior vaccination current use immunosuppressive medication : &gt; 5 mg prednisone equivalent consider high dose immunosuppressive Corticosteroid nasal spray allergic rhinitis permissible Persons use topical steroid mild uncomplicated dermatitis poison ivy contact dermatitis may enrol day therapy complete Inhaled steroid asthma permissible Oral/parenteral corticosteroid give nonchronic condition expect recur permissible length therapy &lt; /= 14 day completion least 30 day prior enrollment . 12 . Medical psychiatric condition occupational responsibility preclude subject compliance protocol . 13 . Any history illegal injection drug use . 14 . Receipt plan receipt inactivate vaccine 14 day prior first vaccination 14 day post second vaccination . 15 . Receipt plan receipt live attenuate vaccine within 30 day prior first vaccination 30 day post second vaccination . 16 . Use experimental agent within 30 day prior vaccination duration subject 's participation study . 17 . Receipt blood product immunoglobulin , include Rhogam , within six month prior vaccination . 18 . Donation unit blood within 56 day prior vaccination plan donation prior 28days follow last vaccination . 19 . Pregnant breastfeed woman . 20 . Active exfoliative skin disorders/conditions , current varicella zoster virus infection , acute skin disorder large magnitude , e.g. , laceration require suture , burn great 2×2 cm . 21 . Any condition , opinion investigator , might interfere assess study objective . 22 . Known allergy egg , aminoglycoside ( include gentamicin ) chicken . 23 . Study personnel . 24 . Allergic reaction vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Smallpox , vaccine , IMVAMUNE , Stratis , parent protocol</keyword>
</DOC>